IL-4/IL-13 inhibition: key factor in the AD pathogenesis
In the pathogenesis of AD, an immune dysfunction with an enhanced Th2 inflammation is as important as the epidermal barrier dysfunction.
Dupilumab, a potent blocker of IL4 and IL13, is the first biologic approved for the treatment of AD. Both cytokines are key mediators of TH2 inflammation, but also lower epidermal barrier proteins [16,17]. Dupilumab impacts both the inflammation and the barrier dysfunction in AD, thus targeting two key factors in AD pathogenesis.
As Prof. Eric Simpson, of Oregon Health & Science University, pointed out, about 50% of patients in the SOLO trial treated with a monotherapy of dupilumab gained an improvement in the EASI by 75% . The efficacy is even higher when combined with topical steroids: 69% of patients gained an EASI 75 response, as was shown in the CHRONOS trial . The one-year data of the CHRONOS trial have shown that the effect persists ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Behcet’s Syndrome and hidradenitis suppurativa Next Article
Psoriasis management online? »
Table of Contents: AAD 2018
Psoriasis: an update
What's hot in atopic dermatitis
Pearls of the posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.